Demant A/S Unsponsored ADR (OTCMKTS:WILYY) Sees Significant Decrease in Short Interest

Key Points

• Short interest plunged: Short interest fell to 36 shares as of April 15 (a 69.5% decline from 118 on March 31), leaving a short-interest ratio of 0.1 days and roughly 0.0% of shares sold short.
• Analyst sentiment improved: Jefferies upgraded Demant from "hold" to "strong-buy" on March 18, and MarketBeat shows a consensus rating of "Buy" (two Strong Buy, one Hold).
• Price and technicals: WILYY opened at $17.12, with a 12‑month range of $13.45–$21.93; the 50‑day and 200‑day moving averages are $14.53 and $16.08 respectively, and the company reports a debt‑to‑equity ratio of 1.65.

Demant A/S Unsponsored ADR (OTCMKTS:WILYY - Get Free Report) was the target of a significant decline in short interest in the month of April. As of April 15th, there was short interest totaling 36 shares, a decline of 69.5% from the March 31st total of 118 shares. Based on an average daily volume of 260 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group raised Demant A/S from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, March 18th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy".

Demant A/S Price Performance

Shares of WILYY stock opened at $17.12 on Friday. Demant A/S has a 12-month low of $13.45 and a 12-month high of $21.93. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65. The stock's 50-day moving average price is $14.53 and its 200-day moving average price is $16.08.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company's flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant's product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.